Response to today's CMA fines on anti-competitive agreements

Warwick Smith, Director General of the British Generic Manufacturers Association (BGMA), said:

"It is wholly unacceptable for companies to manipulate the market artificially to increase the price of generic medicines. The BGMA unreservedly condemns this sort of behaviour. It is the raison d’être of the generic medicines industry to decrease medicines prices through competition and thus to increase access to medicines for patients. The BGMA is proud of the fact that generic medicines prices in the UK are the lowest in Europe. This sort of behaviour is wholly incompatible with our mission. 

“We note that the behaviour involved is historic, and that our member company Accord-UK was not involved, but has assumed liability through acquisition."